This study aims to test a new treatment plan for adults with HIV-1. It uses a mix of vaccines, antibodies, and a medicine called vesatolimod (VES) to see if it can help control the virus without regular HIV medicine. Participants will be given either the treatment or a placebo (a harmless substance that looks like the treatment) to compare results. The study includes several steps, each lasting a different amount of time.
In the first step, participants will receive treatment and continue their regular HIV medicine for about 67 weeks. Then, they will stop their regular medicine for up to 24 weeks to see if the new treatment can keep the virus under control. If the virus comes back, they will restart their medicine for another 24 weeks. If the virus stays under control, they will continue without medicine for another 24 weeks.
- The study lasts up to 110 weeks.
- Participants need to follow all study visits and rules.
- Participants must have started HIV treatment soon after diagnosis.
Participants must meet certain health criteria to join, and women who can become pregnant must use birth control. People with certain medical conditions or allergies cannot participate.